Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 1/2 1Phase 1 1

Status

Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 3

Conditions

Glioblastoma 2Meningeal Carcinomatosis 1Glioma 1

Interventions

Specimen Handling 465Magnetic Resonance Spectroscopy 351pembrolizumab 297Biopsy 251Carboplatin 235Cisplatin 199Cyclophosphamide 191Paclitaxel 167Nivolumab 159Gemcitabine 154Radiotherapy 129Bevacizumab 128Dexamethasone 115fludarabine 103Pemetrexed 102Fluorouracil 96Radiation 94Doxorubicin 94atezolizumab 93Docetaxel 93durvalumab 92venetoclax 91Rituximab 89Oxaliplatin 89Leucovorin 82Capecitabine 79Prednisone 78Lenalidomide 72X-Rays 69Etoposide 69

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
azeliragon × 30 days × Clear all
NCT05635734 2026-05-29

Azeliragon and Chemoradiotherapy in Newly Diagnosed Glioblastoma

Cantex Pharmaceuticals

Phase 1/2 Completed
33 enrolled
CNS

Glioblastoma

NCT06831526 2026-05-29

Neoadjuvant Chemoradiotherapy With or Without Concurrent Azeliragon in Patients With Newly Diagnosed Glioblastoma

Washington University School of Medicine

Phase EARLY_PHASE1 Recruiting
12 enrolled
CNS

Glioblastoma

NCT06724926 2026-05-18

Concurrent Azeliragon With Craniospinal Irradiation

NYU Langone Health

Phase 1 Active not recruiting
21 enrolled
CNS

Glioma, Meningeal Carcinomatosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡